Related references
Note: Only part of the references are listed.882PDPHASE 1/2 STUDY OF ORAL RUCAPARIB: UPDATED PHASE 1 AND PRELIMINARY PHASE 2 RESULTS
R. Kristeleit et al.
ANNALS OF ONCOLOGY (2017)
Cancer Statistics, 2015
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study
Robert L. Coleman et al.
GYNECOLOGIC ONCOLOGY (2015)
Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105
Melinda L. Telli et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
Amit M. Oza et al.
LANCET ONCOLOGY (2015)
Profile of veliparib and its potential in the treatment of solid tumors
Lars M. Wagner
ONCOTARGETS AND THERAPY (2015)
DNA double strand break repair defect and sensitivity to poly ADP-ribose polymerase (PARP) inhibition in human papillomavirus 16-positive head and neck squamous cell carcinoma
Alice N. Weaver et al.
ONCOTARGET (2015)
Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours
G. Del Conte et al.
BRITISH JOURNAL OF CANCER (2014)
Homologous recombination deficiency (HRD) score and niraparib efficacy in high grade ovarian cancer
P. Haluska et al.
EUROPEAN JOURNAL OF CANCER (2014)
Poly(ADP-ribose): An organizer of cellular architecture
Anthony K. L. Leung
JOURNAL OF CELL BIOLOGY (2014)
Identification and Validation of an Anthracycline/Cyclophosphamide-Based Chemotherapy Response Assay in Breast Cancer
Jude M. Mulligan et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses
Jung-Min Lee et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
Joyce F. Liu et al.
LANCET ONCOLOGY (2014)
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
Jonathan Ledermann et al.
LANCET ONCOLOGY (2014)
Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers
Johnathan A. Watkins et al.
BREAST CANCER RESEARCH (2014)
BRCA1-and BRCA2-related mutations: therapeutic implications in ovarian cancer
B. Pothuri
ANNALS OF ONCOLOGY (2013)
BMN673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
Yuqiao Shen et al.
CLINICAL CANCER RESEARCH (2013)
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer
Joyce F. Liu et al.
EUROPEAN JOURNAL OF CANCER (2013)
Pharmacokinetics of orally administered rucaparib in patients with advanced solid tumors.
Geoffrey Shapiro et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer
Maike Ihnen et al.
MOLECULAR CANCER THERAPEUTICS (2013)
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
Shahneen K. Sandhu et al.
LANCET ONCOLOGY (2013)
Mechanisms of resistance to therapies targeting BRCA-mutant cancers
Christopher J. Lord et al.
NATURE MEDICINE (2013)
A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas
Shivaani Kummar et al.
CLINICAL CANCER RESEARCH (2012)
Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer
Stan B. Kaye et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Jonathan Ledermann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Expression of BAG-1 and PARP-1 in Precursor Lesions and Invasive Cervical Cancer Associated with Human Papillomavirus (HPV)
Marcela Kazue Hassumi-Fukasawa et al.
PATHOLOGY & ONCOLOGY RESEARCH (2012)
Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents
Nicolai J. Birkbak et al.
CANCER DISCOVERY (2012)
Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas
Shivaani Kummar et al.
CANCER RESEARCH (2011)
Association of BRCA1 and BRCA2 Mutations With Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in Patients With Ovarian Cancer
Da Yang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
PARP inhibitors: New tools to protect from inflammation
Vincenzo Giansanti et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
Peter C. Fong et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
M. William Audeh et al.
LANCET (2010)
Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130
Denise Campisi Hegan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Investigation of PARP-1, PARP-2, and PARG interactomes by affinity-purification mass spectrometry
Maxim Isabelle et al.
PROTEOME SCIENCE (2010)
PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors
Konstantin J. Dedes et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Poly(ADP-Ribose) Polymerase-1 Inhibitor Treatment Regresses Autochthonous Brca2/p53-Mutant Mammary Tumors In vivo and Delays Tumor Relapse in Combination with Carboplatin
Trevor Hay et al.
CANCER RESEARCH (2009)
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
Ana M. Mendes-Pereira et al.
EMBO MOLECULAR MEDICINE (2009)
Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer
Ursula A. Matulonis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin
Bastiaan Evers et al.
CLINICAL CANCER RESEARCH (2008)
Evolutionary plasticity of genetic interaction networks
Julia Tischler et al.
NATURE GENETICS (2008)
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
Sven Rottenberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites
Jean-Francois Haince et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Essential role for nuclear PTEN in maintaining chromosomal integrity
Wen Hong Shen et al.
CELL (2007)
PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways
Minli Wang et al.
NUCLEIC ACIDS RESEARCH (2006)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
The concept of synthetic lethality in the context of anticancer therapy
WG Kaelin
NATURE REVIEWS CANCER (2005)
In vivo reversion to normal of inherited mutations in humans
R Hirschhorn
JOURNAL OF MEDICAL GENETICS (2003)
Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination
N Schultz et al.
NUCLEIC ACIDS RESEARCH (2003)
Fanconi anemia and DNA repair
M Grompe et al.
HUMAN MOLECULAR GENETICS (2001)
The emerging genetic and molecular basis of Fanconi anaemia
H Joenje et al.
NATURE REVIEWS GENETICS (2001)
DNA double-strand breaks: signaling, repair and the cancer connection
KK Khanna et al.
NATURE GENETICS (2001)
Share Paper
